Initial Data from Allarity Phase 2 Breast Cancer Trial Indicates Potential for Improved Clinical Benefit

 Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced initial results from its European Phase 2 clinical trial evaluating the efficacy of IXEMPRA® in metastatic breast cancer (mBC) patients selected with the DRP®-IXEMPRA® companion diagnostic (CDx) candidate. Researchers prescreened mBC patients using Allarity’s DRP®-IXEMPRA® CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP®-score, and those with scores above 67% were selected for treatment with IXEMPRA®.

Of the 36 patients screened with the DRP®-IXEMPRA® CDx, investigators identified five DRP® positive patients. Among the evaluable patients assessed up to the data evaluation cut-off, there were promising signs of clinical benefit in four out of four evaluable cases:

• One partial responder (PR) (tumor shrinkage of 66%).

• One partial responder (PR) (tumor shrinkage of 59%).

• One patient experienced 24 weeks of stable disease.

• One patient experienced 19 weeks of stable disease.

https://finance.yahoo.com/news/initial-data-allarity-phase-2-134500446.html